#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Biliary cancer metastatic Hyperinsulinism Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome Gaucher's disease type I Juvenile chronic myelomonocytic leukaemia PIK3CA-activated mutation Ventricular fibrillation Idiopathic inflammatory myopathy Sarcoidosis Congenital growth hormone deficiency Hypereosinophilic syndrome Mastocytosis Haemophilia B with anti factor IX Mucous membrane pemphigoid Pulmonary alveolar haemorrhage More trials…

    Learn about Rare Diseases

    Osteosarcoma metastatic – Treatment Haemolytic uraemic syndrome – Basic Information Mastocytosis – Diagnostics Ornithine transcarbamoylase deficiency – Trials in Disease Waldenstrom’s macroglobulinaemia refractory Mantle cell lymphoma refractory – Diagnostics Mastocytosis – Treatment Toxic epidermal necrolysis – Trials in Disease Primary immunodeficiency syndrome – Life with Disease Alexander disease – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Deucrictibant Lenacapavir Retifanlimab Cyclophosphamide Corticosteroids, Plain Somatostatin Metoprolol Tartrate Octocog Alfa Rezpegaldesleukin Mifamurtide Rigosertib Sodium Dazodalibep SIGVOTATUG VEDOTIN ANXV Adagrasib Baclofen Ivabradine SELTOREXANT Benfotiamine Sacituzumab Tirumotecan More therapies…

    Learn about Your Condition

    Paraesthesia Liposarcoma metastatic Pancreatic carcinoma recurrent Liver transplant Neoplasm Heart disease congenital Laparotomy Burning mouth syndrome Retinoblastoma Hyperglycaemia Peripheral artery restenosis Venous thrombosis Small for dates baby Neuralgia Follicular lymphoma stage III More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Neoplasm malignant

  • Continued Treatment Study for Adults with Advanced Cancer Using Pemigatinib

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Pemigatinib
    Italy

  • Study on the Safety and Effectiveness of REGN7075 and Cemiplimab, with or without Chemotherapy, for Patients with Advanced Solid Tumors

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Regn7075
    • Tipiracil Hydrochloride
    • Trifluridine
    France The Netherlands Poland Spain

  • Study on the Safety and Effects of LY2880070 and Gemcitabine in Patients with Advanced or Metastatic Cancer, Focusing on Ovarian Cancer

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Ovarian cancer metastatic
    • Neoplasm malignant
    • Ovarian cancer
    Investigated Drugs:
    • Gemcitabine
    • Gemcitabine Hydrochloride
    Croatia Poland

  • Study of Metronomic Oral Vinorelbine with Durvalumab and Tremelimumab for Patients with Advanced Solid Tumors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Durvalumab
    France

  • Study of ICT01 and Pembrolizumab for Patients with Advanced-Stage, Relapsed/Refractory Cancer

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Ict01
    • Pembrolizumab
    Belgium France Germany Spain

  • Study on the Long-Term Safety of Sacituzumab Govitecan for Patients with Metastatic Solid Tumors

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neoplasm malignant
    Investigated Drugs:
    • Sacituzumab Govitecan
    Belgium France Spain
Previous Page
1 … 19 20 21

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!